aTyr Pharma Inc

aTyr Pharma Inc. is a clinical-stage biotherapeutics company. It develops medicines derived from extracellular tRNA synthetases to address rare inflammatory and immunological diseases, including interstitial lung diseases (ILDs) and fibrosis. Operating within the Healthcare sector, specifically Biotechnology, aTyr Pharma focuses on active tRNA synthetase fragments. Its lead candidate, efzofitimod (ATYR1923), is in clinical trials for pulmonary sarcoidosis and ILDs. Preclinical programs include ATYR0101 for fibrosis and ATYR0750 for liver disorders, aiming to restore immune balance and improve patient outcomes. Keep updated on the latest share price changes by adding ATYR stock to your eToro watchlist. This content was generated by artificial intelligence. We cannot guarantee the accuracy, completeness, or timeliness of the information provided.